A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

Disease Name: 
Multiple Myeloma (MM)
Study Status: 
Date: 
August 7, 2025